相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
S-W Han et al.
BRITISH JOURNAL OF CANCER (2009)
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
C. Pinto et al.
BRITISH JOURNAL OF CANCER (2009)
Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
F. Kullmann et al.
BRITISH JOURNAL OF CANCER (2009)
KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer
Antonio Jimeno et al.
CANCER JOURNAL (2009)
Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment
Jaume Capdevila et al.
CANCER TREATMENT REVIEWS (2009)
An orthotopic nude mouse model for preclinical research of gastric cardia cancer
Sarah Bhargava et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
Gastric cancer in the era of molecularly targeted agents: current drug development strategies
Hendrik-Tobias Arkenau
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Cetuximab, its clinical use and future perspectives
Fernando Rivera et al.
ANTI-CANCER DRUGS (2008)
Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity
Masayasu Hara et al.
CANCER SCIENCE (2008)
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer
Meredith A. Morgan et al.
CLINICAL CANCER RESEARCH (2008)
Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity
Howard Safran et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery
Gennaro Galizia et al.
WORLD JOURNAL OF SURGERY (2007)
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB
H. L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR
D Balin-Gauthier et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world
Farin Kamangar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice
S Kim et al.
CLINICAL CANCER RESEARCH (2006)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Differential responses by pancreatic carcinoma cell lines to prolonged exposure to erbitux (IMC-C225) anti-EGFR antibody
ZQ Huang et al.
JOURNAL OF SURGICAL RESEARCH (2003)
Treatment of pancreatic cancer xenografts with erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation
DJ Buchsbaum et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
分享论文
